natgillin/translations-raw huggingface dataset:
Compounds according to any one of claims 1 to 4, wherein R4 is benzyl, cycloalkyl, phenylcycloalkyl, adamantyl, phenyl, indolyl, pyrazolyl, pyrrolyl or thiazolyl, wherein benzyl, cycloalkyl, phenylcycloalkyl, phenyl, indolyl, pyrazolyl, pyrrolyl and thiazolyl are optionally substituted with one to three substituents independently selected from alkyl, cycloalkyl, alkoxy, hydroxy, halogen, trifluormethyl, trifluoromethoxy, benzyl, phenyl and phenyl substituted with one to three substituents independently selected from alkyl, halogen and trifluoromethyl. 
Spojevi prema bilo kojem od zahtjeva 1 do 4, naznačeni time, da R4 je benzil, cikloalkil, fenilcikloalkii, adamantil, fenil, indolil, pirazolil, pirolil ili tiazolil, gdje benzil, cikloalkil, fenilcikloalkii, fenil, indolil, pirazolil, pirolil i tiazolil su po izboru supstituirani jednim do tri supstituenta neovisno odabranima od alkila, cikloalkila, alkoksi, hidroksi, halogena, trifluormetila, trifluorometoksi, benzila, fenila, a fenil je supstituiran jednim do tri supstituenta neovisno odabranima od alkila, halogena i trifluorometila.
A pharmaceutical composition comprising a compound in accordance with any one of claims 1 to 13 and a therapeutically inert carrier. 
Farmaceutski sastav, naznačen time, da obuhvaća spoj prema bilo kojem od zahtjeva 1 do 13, i terapeutski inertan nosač.
A pharmaceutical composition according to claim 21, wherein the compound is the compound of claim 17. 
Farmaceutski sastav prema zahtjevu 21, naznačen time, da spoj je takav spoj da je u skladu sa zahtjevom 17.
A compound according to claim 17 for use in the treatment and prophylaxis of diabetes, obesity, eating disorders, dyslipidemia and hypertension. 
Spoj prema zahtjevu 17, naznačen time, da je za uporabu u liječenju i profilaksi dijabetesa, pretilosti, poremećaja hranjenja, dislipidemije i hipertenzije.
The metastin derivative according to claim 1 or 2, or a salt thereof, for use as an agent for improving gonadal function. 
Derivat metastina prema zahtjevu 1 ili 2, ili njegova sol, naznačen(a) time, da se koristi kao sredstvo za poboljšanje gonadne funkcije.
The metastin derivative according to claim 1 or 2, or a salt thereof, for use as an agent for inducing or stimulating ovulation. 
Derivat metastina prema zahtjevu 1 ili 2, ili njegova sol, naznačen(a) time, da se koristi kao sredstvo za induciranje ili stimuliranje ovulacije.
Use of metastin derivative according to claim 1 or 2, or a salt thereof, in the manufacture of a medicament for preventing or treating choriocarcinoma, hydatid mole, invasive mole, miscarriage, fetal hypoplasia, abnormal glucose metabolism, abnormal lipid metabolism or induction of delivery. 
Uporaba derivata metastina prema zahtjevu 1 ili 2, ili njegove soli, naznačena time, da je za proizvodnju lijeka za prevenciju ili liječenje korionkarcinoma, hidatidnih madeža, invazivnih madeža, pobačaja, fetalne hipoplazije, nepravilnog metabolizma glukoze, nepravilnog metabolizma lipida ili za induciranje porođaja.
Use of metastin derivative according to claim 1 or 2, or a salt thereof, in the manufacture of a medicament for improving gonadal function. 
Uporaba derivata metastina prema zahtjevu 1 ili 2, ili njegove soli, naznačena time, da je za proizvodnju lijeka za poboljšanje gonadne funkcije.
The metastin derivative according to claim 1 or 2, or a salt thereof, for use as a down-regulating agent for human OT7T175 (metastin receptor) protein consisting of the amino acid sequence represented by SEQ ID NO: 9. 
Derivat metastina prema zahtjevu 1 ili 2, ili njegova sol, naznačen(a) time, da se koristi kao sredstvo za down-regulaciju humanih OT7T175 (metastin receptor) proteina koji se sastoje od amino kiselinske sekvence predstavljene sa SEQ ID NO: 9.
The metastin derivative according to claim 22 or 23, or a salt thereof, for use as an agent for preventing or treating hormone-dependent cancer. 
Derivat metastina prema zahtjevu 22 ili 23, ili njegova sol, naznačen(a) time, da se koristi kao sredstvo za prevenciju ili liječenje raka ovisnog o hormonima.
An isolated antibody or antigen binding fragment thereof that competes for binding to Ang-2 with the antibody deposited as ATCC Accession Number PTA-7260 (mAb 3.19.3) which binds Ang-1 and Ang-2 with a Kd of less than 100 picomolar, as measured by high resolution surface plasmon resonance. 
Izolirano protutijelo, ili njegov dio koji se veže na antigen, naznačeni time da se natječu za vezanje na Ang-2 s protutijelom pohranjenim kao ATCC, urudžbeni broj PTA-7260 (mAb 3.19.3), koje se veže na Ang-1 i Ang-2 s Kd od manje od 100 pikomolara, mjereno rezonancijom površinskih plazmona visoke rezolucije.
The use according to claim 9, wherein said malignant tumor is selected from the group consisting of: melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and epidermoid carcinoma. 
Upotreba prema 9. patentnom zahtjevu, naznačena time da se taj zloćudni tumor bira iz skupine koju čine: melanom, karcinom malih plućnih stanica, karcinom ne-malih plućnih stanica, gliom, karcinom jetre, tumor štitnjače, karcinom želuca, karcinom prostate, karcinom dojke, karcinom jajnika, karcinom mjehura, karcinom pluća, glioblastom, karcinom endometrija, karcinom bubrega, karcinom debelog crijeva, karcinom gušterače i epidermalni karcinom.
The antibody or antigen binding fragment of claim 11, wherein said malignant tumor is selected from the group consisting of: melanoma, small cell lung cancer, non-small cell lung cancer, glioma, hepatocellular (liver) carcinoma, thyroid tumor, gastric (stomach) cancer, prostate cancer, breast cancer, ovarian cancer, bladder cancer, lung cancer, glioblastoma, endometrial cancer, kidney cancer, colon cancer, pancreatic cancer, and epidermoid carcinoma. 
Protutijelo, ili njegov dio koji se veže na antigen iz patentnog zahtjeva 11., naznačeni time da se taj zloćudni tumor bira iz skupine koju čine: melanom, karcinom malih plućnih stanica, karcinom ne-malih plućnih stanica, gliom, karcinom jetre, tumor štitnjače, karcinom želuca, karcinom prostate, karcinom dojke, karcinom jajnika, karcinom mjehura, karcinom pluća, glioblastom, karcinom endometrija, karcinom bubrega, karcinom debelog crijeva, karcinom gušterače i epidermalni karcinom.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-dichloromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1 H-pirazol-4-karboksilna kiselina (9-diklorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A composition according to claim 1, which comprises as component (A) the compound 3-difluoromethyl-1-methyl-1H-pyrazole-4-carboxylic acid (9-difluoromethylidenebenzonorbornene-5-yl)amide and as component (B) fluopyram. 
Pripravak prema zahtjevu 1, naznačen time da kao komponentu (A) sadrži spoj 3-difluorometil-1-metil-1H-pirazol-4-karboksilna kiselina (9-difluorometiliden-benzonorbornen-5-il)amid, te kao komponentu (B) ciprodinil.
A party balloon according to claim 1, wherein the outer end region (57) of the strip of insulating material (53) which is of enlarged width is in the form of an arrowhead shape enlargement. 
Balon za zabave u skladu s patentnim zahtjevom 1, naznačen time što vanjski krajnji predio (57) trake od izolacijskog materijala (53), koji ima povećanu širinu, ima proširenje koje ima oblik strelice.
A party balloon according to claim 1 or 2, wherein the second region (67) of enlarged width of the strip of insulating material (53) is of approximately circular shape. 
Balon za zabave u skladu s patentnim zahtjevom 1 ili 2, naznačen time što drugi predio (67) trake od izolacijskog materijala (53), koji ima povećanu širinu, ima približno kružni oblik.
the stream of ethane is subjected to a catalytic oxydehydrogenation producing a gas mixture containing ethylene, unconverted ethane, water and secondary constituents; said gas mixture is optionally washed and dried thus producing a dry gas mixture; after an optional additional purification step, the dry gas mixture is then conveyed to a chlorination reactor supplied with a flow of chlorine so that at least 10% of the ethylene is converted to 1,2-dichloroethane; 
struja etana je podvrgnuta katalitičkoj oksidehidrogenaciji koja daje plinsku mješavinu koja sadrži etilen, nepretvoreni etan, vodu i sekundarne sastojke; navedena plinska mješavina se proizvoljno ispire i suši te se tako dobiva suha plinska mješavina; nakon proizvoljnog dodatnog koraka pročišćavanja, suha plinska mješavina se tada prebacuje u reaktor za kloriranje u koji se dovodi struja klora tako da je barem 10% etilena pretvoreno u 1,2-dikloroetan;
Process according to Claim 1, characterized in that the stream of ethane contains at least 98 vol% of ethane. 
Postupak prema zahtjevu 1, naznačen time da struja etana sadrži barem 98 vol% etana.
Process according to Claim 1, characterized in that during step b), said gas mixture is washed and dried, thus producing a dry gas mixture. 
Postupak prema zahtjevu 1, naznačen time da tijekom koraka b), navedena plinska mješavina je isprana i osušena, te se tako dobiva suha plinska mješavina.
Process according to Claim 1, characterized in that during step c), the flow of chlorine is such that at most 90% of the ethylene is converted to 1,2-dichloroethane. 
Postupak prema zahtjevu 1, naznačen time da je tijekom koraka c), struja klora takva da se najviše 90% etilena pretvara u 1,2-dikloroetan.
Process according to Claim 1, characterized in that during step c), the flow of chlorine is such that at least 40% of the ethylene is converted to 1,2-dichloroethane. 
Postupak prema zahtjevu 1, naznačen time da je tijekom koraka c), struja klora takva da se barem 40% etilena pretvara u 1,2-dikloroetan.
the stream of ethane is subjected to a catalytic oxydehydrogenation at a temperature less than or equal to 650°C producing a gas mixture containing ethylene, unconverted ethane, water and secondary constituents; 
struja etana je podvrgnuta katalitičkoj oksidehidrogenaciji na temperaturi manjoj od ili jednakoj 650°C koja daje plinsku mješavinu koja sadrži etilen, nepretvoreni etan, vodu i sekundarne sastojke;
after an optional additional purification step, the dry gas mixture is then conveyed to a chlorination reactor supplied with a flow of chlorine so that at least 10% of the ethylene is converted to 1,2-dichloroethane; 
nakon proizvoljnog dodatnog koraka pročišćavanja, suha plinska mješavina se tada prebacuje u reaktor za kloriranje u koji se dovodi struja klora tako da je barem 10% etilena pretvoreno u 1,2-dikloroetan;
the 1,2-dichloroethane formed in the chlorination reactor is isolated from the stream of products derived from the chlorination reactor; 
1,2-dikloroetan dobiven u reaktoru za kloriranje je izoliran iz struje produkata dobivenih iz reaktora za kloriranje;
a stream of ethane is subjected to a catalytic oxydehydrogenation producing a gas mixture containing ethylene, unconverted ethane, water and secondary constituents; 
struja etana je podvrgnuta katalitičkoj oksidehidrogenaciji koja daje plinsku mješavinu koja sadrži etilen, nepretvoreni etan, vodu i sekundarne sastojke;
the 1,2-dichloroethane obtained is subjected to a pyrolysis thus producing vinyl chloride. 
dobiveni 1,2-dikloroetan je podvrgnut pirolizi te se tako dobiva vinil klorid.
the 1,2-dichloroethane obtained is subjected to a pyrolysis thus producing VC; and 
dobiveni 1,2-dikloroetan je podvrgnut pirolizi te se tako dobiva vinil klorid; i
the vinyl chloride is polymerized to produce polyvinyl chloride. 
vinil klorid je podvrgnut polimerizaciji da se dobije polivinil klorid.
Process according to Claims 1 to 11, according to which mixed oxides containing both Mo and V, W and V or Mo, W and V are used as catalytic systems to carry out the catalytic oxydehydrogenation. 
Postupak prema zahtjevima 1 do 11, naznačen time da miješani oksidi koji sadrže oboje Mo i V, W i V ili Mo, W i V se koriste kao katalitički sustavi za provođenje katalitičke oksidehidrogenacije.
and R2 together with the nitrogen atom to which they are attached form a 5 to 7 membered heterocyclic ring containing at least 1 nitrogen atom or 1 nitrogen and 1 additional heteroatom e.g. selected from N or O, or R1 is hydroxy and R2 is formyl; 
i R2 zajedno s atomom dušika na koji su priključeni tvore 5 do 7-člani heterociklički prsten koji sadrži barem 1 atom dušika ili 1 atom dušika i 1 dodatni heteroatom primjerice odabran od N ili O, ili R, je hidroksi i R1 je formil;
A compound according to one of the claims 1 to 4, selected from the group consisting of 
Spoj prema jednom od zahtjeva 1 do 6, naznačen time, da je odabran iz skupine koju čine:
A pharmaceutical drug composition according to claim 13, further comprising another pharmaceutically active agent. 
Farmaceutski ljekoviti sastav prema zahtjevu 13, naznačen time, da nadalje sadrži dodatno farmaceutski aktivno sredstvo.
A unit (1) according to claim 7, wherein the posts (2,2a), the spacing elements (4) and the angular section bars (5) have the same height. 
Građevinski element (1) prema zahtjevu 7, naznačen time, da grede (2, 2a), distantni klinovi (4) i kutne profilne poluge (5) imaju jednaku visinu.
The pirfenidone for use or use of claim 5 wherein the patient is discontinuing smoking within 4 weeks prior to the administration of pirfenidone. 
Pirfenidon za upotrebu ili upotreba prema zahtjevu 5, naznačen time, što je pacijent prekinuo pušenje u toku 4 tjedna prije davanja pirfenidona.
the first and second connecting members (44) are hooked shoes adapted for hooking into the openings in the backrest (3, 4) or the side pieces (5), and 
prvo i drugo sredstvo za spajanje (44) sa uskočne kopče prilagođene za kopčanje u otvore u naslonu za leđa (3, 4) ili u bočnim elementima (5), i
A safety bow according to claim 1, wherein the third connecting member (46) is arranged for detachable fastening to the hole or detachable fastening via a bracket to the hole in the plate, preferably by snapping. 
Sigurnosni luk prema zahtjevu 1, naznačen time da je treće sredstvo za spajanje (46) predviđeno za rastavljivo učvršćivanje u otvor ili rastavljivo učvršćivanje pomoću potpornika u otvor u ploči, poželjno na uskočni način.
The use of a safety bow according to any of the claims 1 to 15, in a children's chair, such as a chair with a seat plate and a foot plate which may be moved to different height and depth positions by being moved in and out of tracks in the side pieces of the chair, preferably together with a children's harness. 
Uporaba sigurnosnog luka prema bilo kojem od zahtjeva 1 do 15, za dječji stolac, kao što je stolac sa pločom za sjedenje i pločom za noge koji se jednostavno namješta u različite položaje po visini i dubini, tako da ih se pomakne u i iz vodilica u bočnim elementima stolca, poželjno zajedno sa dječjim sigurnosnim pojasom.
A compound according to claim 1 or claim 2 for use as a medicament. 
Spoj prema zahtjevu 1 ili zahtjevu 2 za uporabu kao lijek.
A compound according to claim 1 or claim 2 for use in the treatment of cancer, in particular solid tumors, more particularly breast, colon, lung and prostate tumors. 
Spoj prema zahtjevu 1 ili zahtjevu 2 za uporabu u liječenju raka, posebno solidnih tumora, točnije tumora dojke, kolona, pluća i prostate.
forming a biomass slurry by mixing biomass with a working fluid; 
formiranje kaše biomase miješanjem biomase s radnom tekućinom;
inducing the biomass slurry to flow through an inlet (4) into a passage (3) of a fluid processor (1), the passage (3) having a substantially constant diameter; 
poticanje kaše biomase da protječe kroz ulaz (4) u prolaz (3) uređaja za obradu tekućina (1), prolaz (3) ima u biti stalan promjer;
introducing steam to a nozzle (16) communicating with the passage (3), the nozzle (16) having a nozzle inlet, a nozzle throat and a nozzle outlet, the nozzle throat having a smaller cross sectional area than either the nozzle inlet or nozzle outlet;and accelerating the steam through the nozzle throat and injecting the high velocity steam into the slurry flowing through the passage (3). 
uvođenje pare u mlaznicu (16) koja je povezana s prolazom (3), mlaznica (16) ima svoj ulaz, grlo i izlaz, grlo ima manje područje poprečnog presjeka ili od ulaza ili izlaza mlaznice; i ubrzavanje pare kroz grlo mlaznice i ubrizgavanje pare velike brzine u kašu koja protječe kroz prolaz (3).
The process of either Claim 3 or Claim 4, wherein the first and/or second catalysts are injected into the slurry through an additive port located in the passage (3) immediately downstream of the nozzle (16). 
Postupak prema zahtjevu 3 ili zahtjevu 4, gdje se prvi i/ili drugi katalizator ubrizgavaju u kašu preko dodatnog ulaza koji se nalazi u prolazu (3) odmah niz mlaznicu (16).
a mixing container (22) adapted to mix a supply of biomass and a supply of working fluid to form a biomass slurry; 
Uređaj za obradu biomase koji obuhvaća: spremnik za miješanje (22) prilagođen za miješanje biomase i radne tekućine da nastane kaša biomase;
The apparatus of Claim 15, wherein the additive port is located in the passage (3) adjacent the nozzle (16). 
Uređaj prema zahtjevu 15, gdje se dodatni ulaz nalazi u prolazu (3) uz mlaznicu (16).
The apparatus of either Claim 15 or Claim 16, wherein the additive port is located in the passage (3) immediately downstream of the nozzle (16). 
Uređaj prema zahtjevu 15 ili zahtjevu 16, gdje se dodatni ulaz nalazi u prolazu (3) odmah iza mlaznice (16).
The apparatus of any of Claims 11 to 17 further comprising a recirculation circuit which is adapted to return slurry from the fluid passage outlet (5) to the mixing container. 
Uređaj prema bilo kojem od zahtjeva 11 do 17 koji dalje obuhvaća recirkulacijski krug koji je prilagođen da vraća kašu iz izlaza (5) prolaza u spremnik za miješanje.
The apparatus of any of Claims 11 to 19 further comprising a plurality of sensors (27,38,42) adapted to measure pressure upstream and downstream of the fluid processor (1). 
Uređaj prema bilo kojem od zahtjeva 11 do 19 koji dalje obuhvaća niz senzora (27,38,42) prilagođenih za mjerenje tlaka prije i nakon uređaja za obradu tekućina (1).
The apparatus of any of Claims 11 to 20, wherein the mixing container (22) includes agitation means for mixing the contents thereof. 
Uređaj prema bilo kojem od zahtjeva 11 do 20, gdje spremnik za miješanje (22) ima sredstva za miješanje sadržaja koji se u njemu nalazi.
The apparatus of any of Claims 11 to 22, wherein the nozzle (16) is annular and circumscribes the fluid passage (3). 
Uređaj prema bilo kojem od zahtjeva 11 do 22, gdje je mlaznica (16) anularna i okružuje prolaz (3).
or, when n is 2, adjacent R1 together define an olefinic bond; 
ili, kada je n jednako 2, susjedni R1 zajedno definiraju olefinsku vezu;
or when the gem R1 is -OR3, that R2 may also be -C(=O)OH or a pharmaceutically acceptable ester thereof; 
ili kada je susjedni R1 jednak -OR3, tada R2 također može biti -C(=O)OH ili farmaceutski prihvatljivi ester spoja;
A compound according to claim 11, for use in the treatment or prophylaxis of HIV. 
Spoj prema zahtjevu 11, za uporabu u liječenju ili prevenciji HIV-a.
A compound for use according to claim 12, wherein the HIV is multiresistant HIV. 
Spoj za uporabu prema zahtjevu 12, gdje je HIV multirezistentni HIV.
A compound according to claim 13, wherein the reverse transcriptase of the multiresistant HIV bears at least one mutation that allows an obligate chain terminating nucleoside- or nucleotide phosphate to be excised from the nascent DNA strand by ATP- or pyrophosphate-mediated excision. 
Spoj prema zahtjevu 13, gdje reverzna transkriptaza multirezistentnog HIV-a nosi barem jednu mutaciju koja omogućuje da obvezni krajevi lanca nukleozid- ili nukleotid- fosfati budu izrezani iz nascentnog (rastućeg) DNA lanca pomoću ATP- ili pirofosfat- posredovanog izrezivanja.
A compound according claim 11 for use in the treatment or prevention of HIV infection. 
Spoj prema zahtjevu 11 za uporabu u liječenju ili prevenciji zaraze HIV-om.
A compound for use according claim 19, wherein the HIV is multiresistant HIV. 
Spoj za uporabu prema zahtjevu 19, gdje je HIV multirezistentni HIV.
The pirfenidone or use of claim 5 wherein the patient is discontinuing smoking within 4 weeks prior to the administration of pirfenidone. 
Pirfenidon za upotrebu ili upotreba prema zahtjevu 5, naznačen time, što je pacijent prekinuo pušenje u toku 4 tjedna prije davanja pirfenidona.
A protein layer according to claim 8, wherein the protein layer comprises protein protomers of two types, the first type of protomer comprising a first monomer which is a monomer of said first oligomer assembly belonging to a dihedral point group of order O, where O equals 3, 4, or 6, genetically fused to a second monomer which is a monomer of said second oligmer assembly, said second oligomer assembly being a hetrologous oligomer assembly belonging to a cyclic point group of order 2, and the second type of protomer comprising a third monomer which is a monomer of said second oligomer assembly, genetically fused to a fourth monomer which is a monomer of a third oligomer assembly, said third oligomer assembly belonging to a dihedral point group of order 2 or O. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da su protomeri heterologni u odnosu na monomere, a proteinski sloj sadrži dva tipa proteinskih protomera, prva vrsta protomera sadrži prvi monomer, koji je monomer navedenog prvog skupa oligomera koji pripada dihedralnoj točkinoj grupi reda O, pri čemu O jest jednako 3, 4 ili 6, genetičkim putem spojen na drugi monomer, koji je monomer navedenog drugog skupa oligomera, pri čemu je navedeni drugi skup oligomera heterologni skup oligomera koji pripada cikličkoj točkinoj grupi reda 2, te druga vrsta protomera sadrži treći monomer, koji je monomer navedenog drugog skupa oligomera koji je genetičkim putem spojen na četvrti monomer, koji je monomer trećeg skupa oligomera, pri čemu treći skup oligomera pripada dihedralnoj točkinoj grupi reda 2 ili O.
a component of the protein layer being an affinity tag, the molecular entities being attached to respective affinity tags; 
dio proteinskog sloja je afinitetna oznaka, a molekularni entitet pričvršćen je na odgovarajuću afinitetnu oznaku;
the molecular entity comprising a protein having a peptide affinity tag attached to a component of the protein layer; 
molekularni entitet koji sadrži protein s peptidnom afinitetnom oznakom pričvršćenom na komponentu proteinskog sloja;
the molecular entity comprising a protein, and both of a component of the protein layer and the molecular entity having respective affinity tags attached to each other; or the molecular entities being genetically fused within a component of the protein layer. 
molekularni entitet sadrži protein, a komponenta proteinskog sloja i molekularni entitet imaju odgovarajuće afinitetne oznake spojene jedna na drugu; ili molekularni entiteti genetičkim su putem spojeni unutar komponente proteinskog sloja,
A medication delivery device (1) comprising: 
Naprava za unos lijeka (1), koja se sastoji od:
The medication delivery device (1) according to claim 13, characterized in that the stop means comprises a clutch means (24) which is non-rotatably engaged with the drive sleeve (19). 
Naprava za unos lijeka (1) u skladu s patentnim zahtjevom 13, naznačena time što zaustavni element sadrži spojku (24), koja je na nezakretljiv način spojena s pogonskom prstenom (19).
The medication delivery device (1) according to any of claims 11 to 14, comprising a dosing mechanism which includes the piston rod (17) and the drive device, the dosing mechanism further comprising: 
Naprava za unos lijeka (1) u skladu s bilo kojim od patentnih zahtjeva 11 do 14, naznačena time što sadrži mehanizam za doziranje, koji sadrži klip (17) i pogonsku napravu, gdje mehanizam za doziranje dodatno sadrži: